Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
V.ARCH
Alternate Symbol(s):
ACHFF
Healthcare
Biotechnology
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is...
LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(124)
•••
Viking2233
X
Post by
Viking2233
on Apr 07, 2025 10:03am
New low achieved
We achieve a new trading low. I assume markets see nothing good in Arch with all this Trump daily economic attacks. Friday we clised at $1.74 but we open today at $1.27 down 30% on 17,000 shares
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Mar 21, 2025 8:38am
Toronto Phase 2 Sites
Well what news can we discuss considering management remains to be silent on our phase 2 international AKI study currently dosing at 5 sites in Turkey and 1 site in Calgary. The trial is set to dose
...more
(4)
•••
Cb27743
X
Post by
Cb27743
on Mar 07, 2025 10:28am
Outside the box Capital
25k a month contract to do what? Looks like nothing so far. Arch is a great company, but Arch is still at 2-5000 in volume day traded and still no market awareness of the positives that are going on
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Feb 03, 2025 7:45am
New Press Release - Shares for Interest Debt Settlement
TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $57,246.57 in interest accrued up to February 1, 2025 on the one...
read article.
(72)
•••
PeptidePete
X
Post by
PeptidePete
on Jan 25, 2025 1:40pm
Arch Biopartners - Insider Buying - CEO
After recent buying, the CEO now owns 9,221,310 Shares!
(72)
•••
PeptidePete
X
Post by
PeptidePete
on Jan 25, 2025 1:37pm
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stock
Arch Biopartners: Top 10 Undervalued Healthcare Sector Stocks - Globe and Mail
(124)
•••
Viking2233
X
Post by
Viking2233
on Jan 19, 2025 6:00pm
Did you know….
Arch Is No One Trick Pony Arch Bio is not your typical start Pharma play where all your eggs are in one basket. This a big reason why I am so bullish on Arch. Lets
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Jan 17, 2025 10:04am
2025 the Year of Arch
2025 Bullish Upside This is the year for Arch to soar! Lets look at a few reasons why below: Arch has proven that metablok is safe to use at a much higher dose then previously
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Jan 08, 2025 9:39am
Ontario Sites
So management news releases they have ethics approval at two Ontario sites but require additional internal approvals before dosing starts. I am not sure how to react. I guess it provides additional
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Dec 30, 2024 1:40pm
2025
So in a few days we will enter 2025. What will this New Year bring to Arch shareholders? I hope that management decides to bring transparency and communication to the markets, communication as
...more
(124)
•••
Viking2233
X
Comment by
Viking2233
on Dec 09, 2024 1:18pm
RE:PONTIAC Cilastatin market update?
Welll I doubt that date is achievable and quite frankly this trial is not controlled by Arch. I think Arch's current AKi trial that involves three Canadian sites should serve as a guideline and
...more
(4)
•••
Cb27743
X
Post by
Cb27743
on Dec 09, 2024 12:48pm
PONTIAC Cilastatin market update?
The PONTIAC clinical team sponsoring the trial is based in Calgary and is currently preparing to submit a Clinical Trial Application (CTA) to Health Canada to proceed with the trial by the fourth
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Dec 04, 2024 12:10pm
My Concerns…..
Well another week has passed and more patients dosed but I do have concerns, not with the science, not with the drug, not with trials but with the lack of communication and the hoops a company has to
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Nov 24, 2024 3:41pm
Silence Continues ………
But so does the nefarious shorting algorithms! In my humble opinion the lack of communication and updates, just plays into the hands of those shorting. I
...more
(124)
•••
Viking2233
X
Post by
Viking2233
on Nov 17, 2024 5:28pm
Nothing but Silence
Arch update Well I wish I had something positive to report. I only have my observations and opinions. We are 9 months into dosing in Turkey at 5 sites. Arch management reluctant
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
CONTENT CREATORS: Learn How to Become a Stockhouse Contributor
Tribe Property Achieves Record Revenue of $8.4 million and First Positive Adjusted EBITDA Quarter